Chemistry: analytical and immunological testing – Involving an insoluble carrier for immobilizing immunochemicals
Reexamination Certificate
2011-02-15
2011-02-15
Minnifield, N. M (Department: 1645)
Chemistry: analytical and immunological testing
Involving an insoluble carrier for immobilizing immunochemicals
C436S523000
Reexamination Certificate
active
07888135
ABSTRACT:
A sensitive, multicomponent diagnostic test for infection withT. cruzi, the causative agent of Chagas disease, including methods of making and methods of use. Also provided is a method for screeningT. cruzipolypeptides to identify antigenic polypeptides for inclusion as components of the diagnostic test, as well as compositions containing antigenicT. cruzipolypeptides.
REFERENCES:
patent: 5232844 (1993-08-01), Horowitz et al.
patent: 5756662 (1998-05-01), Reed
patent: 6368827 (2002-04-01), Tarleton et al.
patent: 6403103 (2002-06-01), Paranhos-Baccala et al.
patent: 6419933 (2002-07-01), Reed et al.
patent: 6875584 (2005-04-01), Tarleton et al.
patent: 2004/0241729 (2004-12-01), Liew
patent: 2005/0158347 (2005-07-01), Tarleton et al.
patent: 2005/0244505 (2005-11-01), Higbee et al.
patent: 2006/0228300 (2006-10-01), Chang et al.
patent: WO 2005/111622 (2005-11-01), None
Luhrs et al. (Vaccine, 21:3058-3069, 2003).
Mezzasoma et al. (Clin. Chem., 48:121-130, Jan. 2002).
He et al. (Clin. Diag. Lab. Immunol., 7:899-903, 2000).
Atwood et al., “TheTrypanosoma cruziproteome,”Science, 2005, 309(5733):473-476.
Bio-Plex System and Suspension Array Technology. Bio-Rad Laboratories. Available online [retrieved Apr. 18, 2005]. Retrieved from the Internet: <http://www.biorad.com/B2B/BioRad/product/br—category.jsp?BV—SessionID=@@@@0429302147.1179497201@@@@&BV—EngineID=ccchaddkmhhmfjkcfngcfkmdhkkdflm.0&categoryPath=%2fCatalogs%2fLife+Science+Research%2fMultiplex+Suspension+Array+System%2fBio-Plex+System+and+Suspension+Array+Technology&catLevel=4&divName=Corporate&loggedIn=false&lang=English&country=HQ&catOID-24083&isPA=false&serviceLevel=Lit+Request>; 5 pgs.
Bio-Plex Workstation and Software. Bio-Rad Laboratories. Available online [retrieved Apr. 18, 2005]. Retrieved from the Internet: <http://www.biorad.com/B2B/BioRad/product/br—category.jsp?BV—SessionID=@@@@0429302147.1179497201@@@@&BV—EngineID=ccchaddlunfihmfjkcfngcflcmdhkkdflm.0&divName=Life+Science+Research&categoryPath=%2fCatalogs%2fLife+Science+Research%2fMultiplex+Suspension+Array+System%2fBio-Plex+Workstation+and+Software&loggedIn=false&lang—English &catLevel=4&country=HQ&catOID=-24084&isPA=false&serviceLevel=Lit+Request>; 3 pgs.
da Silveira et al., “Chagas disease: recombinantTrypanosoma cruziantigens for serological diagnosis,” 2001,Trends Parasitol., 17(6):286-291.
Dias et al., “The Evolution of Chagas Disease (American Trypanosomiasis) Control after 90 Years since Carlos Chagas Discovery,” 1999,Mem. Inst. Oswaldo Cruz, 94:Supp1.1:103-121.
Donnelly et al., “DNA Vaccines,”Ann.Rev.Immunol. 15:617-648, 1997.
Endresz et al., “Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)pspecific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization,” 1999,Vaccine, 17:50-58.
Etheridge and Tarleton “What is wrong with this test: A high throughput screening ofTrypanosoma cruziantigens for seroligical diagnosis.” Poster. Woods Hole ImmunoParasitology Conference: Woods Hole, MA. Apr. 25-28, 2004. 1 page; Abstract printed in meeting program.
Ferreira et al., “Enzyme-Linked Immunosorbent Assay for Serological Diagnosis of Chagas' Disease Employing aTrypanosoma cruziRecombinant Antigen that Consists of Four Different Peptides,” 2001,J. Clin.Micro., 39(12):4390-4395.
Fifis et al., “Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors,” 2004,J. Immunol., 173:3148-3154.
Fifis et al., “Short peptide sequences containing MHC Class I and/or Class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumor challenge in mice,” 2004,Vaccine, 23:258-266.
Gateway® Cloning. Premier Biosoft International TechNotes. Available online [retrieved Apr. 15, 2005]. Retreived from the Internet: <http://www.premierbiosoft.com/tech—notes/Gateway—Cloning.html>; 6 pgs.
Giovanni, “NIAID Genomics Initiatives,” Internet Article 2004. Retrieved from http://www.niaid.nih.gov/dmid/genomes/brc/PDF/gen—init. , entire document.
Hoffman et al., “Toward clinical trials of DNA vaccines against malaria,” 1997,Immunol. Cell Biol. 75:376-381.
Jones et al., “Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys,” 1999,Vaccine, 17:3065-3071.
Laucella et al., “Frequency of Interferon-γ-Producing T Cells Specific forTrypanosoma cruziinversely correlates with disease severity in chronic human Chagas Disease,” 2004,J. Infect. Dis. Mar. 1;189(5):909-918.
LeBorgne et al., “In Vivo Induction of Specific Cytotoxic T Lumphocytes in Mice and Rhesus Macaques Immunized with DNA Vector Encoding an HIV Epitope Fused with Hepatitis B Surface Antigen,” 1998,Virology. 240:304-315.
Luchtan et al., “TcruziDB: an integratedTrypanosoma cruzigenome,” Nucleic Acids, Res., vol. 32, 2004, pp. D344-D346.
McCluskie et al., “Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates,” 1999,Mol. Med. 5287-5300.
MMWR Morb Mortal Wkly Report. Mar. 15, 2001:51(10):210-2.
“MultiSite Gateway® Three-Fragment Vector Construction Kit.” Instruction Manuel. Invitrogen life technologies. Catalog No. 12537-023. Version C; updated Nov. 29, 2004. Available online [retrieved Apr. 15, 2005]. Retrieved from the Internet: <http://www.invitrogen.com/content/sfs/manuals/multisite—gateway—man.pdf>; 68 pgs.
Nakazawa et al., “Excretory-Secretory Antigens ofTrypanosoma cruziare Potentially Useful for Serodiagnosis of Chronic Chagas' Disease,” 2001,Clin. Diag. Lab. Immunol., 8:1024-1027.
Salomone et al., “Trypanosoma cruziin Persons without Serologic Evidence of Disease, Argentina,” 2003,Emerg. Infect. Dis. Dec;9(12):1558-1562.
Schutze-Redelmeier et al., “Introduction of Exogenous Antigens into the MHC Class 1 Processing and Presentation Pathway byDrosophilaAntennapedia Homeodomain Primes Cytotoxic T Cells in Vivo,” 1996,J. Immunol. 157:650-655.
Schwarze et al., “In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse,” 1999,Science, 285:1569-1572.
Soen et al., “Detection and Characterization of Cellular Immune Responses Using Peptide-MHC Microarrays,” 2003,PloS. Biol., 1:429-438.
Stone et al., “HLA-restricted epitope identification and detection of functional T cell responses by using MHC-peptide and costimulatory microarrays,” 2005,PNAS USA, 102:3744-3749.
Tacket et al., “Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device,” 1999,Vaccine, 17:2826-2829.
“TcruziDB: An integratedTrypanosoma cruziGenome Resource.” Online Database [retrieved May 17, 2007]. Funded by the American Heart Association. Last updated Nov. 7, 2006. Retrieved from the Internet: <http://www.tcruzidb.org/tcruzidb/>:, 2 pgs.
TcruziDB Gene: Tc00.1047053506563.40 (old ID No. 6998.t00004). Encoding eta-tubulin, putative. Available online [retrieved May 18, 2007]. Retrieved from the Internet: <http://www.tcruzidb.org/tcruzidb/showRecord.do?name=GeneRecordClasses.GeneRecordClass&project—id=&primary—key=Tc00.1047053506563.40>; 4 pgs.
TcruziDB Gene: Tc00.1047053411235.9 (old ID No. 11788.t00001). Encoding alpha-tubulin, putative. Available online [retrieved May 18, 2007]. Retrieved from the Internet: <http://www.tcruzidb.org/tcruzidb/showRecord.do?name=GeneRecordClasses.GeneRecordClass&project—id=&primary—key=Tc00.1047053411235.9>; 4 pgs.
Tcru
Etheridge, Jr. Ronald D.
Tarleton Rick L.
Gangle Brian J
Minnifield N. M
Mueting Raasch & Gebhardt, P.A.
University of Georgia Research Foundation Inc.
LandOfFree
Diagnostic assay for Trypanosoma cruzi infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic assay for Trypanosoma cruzi infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic assay for Trypanosoma cruzi infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2630400